|   |  UNITED STATES                      |   |
|--------|------------------------------------------|--------|
|   |  SECURITIES AND EXCHANGE COMMISSION |   |
|   |  WASHINGTON, DC 20549               |   |

|   |  NEVADA                          |   |   |  88-0390828         |   |
|--------|---------------------------------------|--------|--------|--------------------------|--------|
|   |  (State or other jurisdiction of |   |   |  I.R.S. Employer    |   |
|   |  incorporation or organization)  |   |   |  Identification No. |   |

|   |   |  Rontgenlaan 27, 2719 DX                              |   |   |
|--------|--------|------------------------------------------------------------|--------|--------|
|   |   |  Zoetermeer, The Netherlands                          |   |   |
|   |   |  (Address of principal executive offices)             |   |   |
|   |   |                                                       |   |   |
|   |   |  011-31-793-630-129                                   |   |   |
|   |   |  Registrant's telephone number, including area code   |   |   |
|   |   |                                                       |   |   |
|   |   |  N/A                                                  |   |   |
|   |   |  (Former name, former address and former fiscal year, |   |   |
|   |   |  if changed since last report)                        |   |   |
|   |   |                                                       |   |   |

|   |  Large accelerated filer o                                                              |   |   |  Accelerated filer  o   |   |
|--------|----------------------------------------------------------------------------------------------|--------|--------|-----------------------------------|--------|
|   |  Non-accelerated filer o   (Do not check if a smaller reporting company) |   |   |  Smaller reporting company x |   |
|   |                                                                                         |   |   |                              |   |

----

| Item #       |   | Description                                                                           |   | Page Numbers |
|--------------|--------|---------------------------------------------------------------------------------------|--------|--------------|
|         |   |                                                                                  |   |         |   |
|         |   | PART I                                                                                |   |  4      |   |
|         |   |                                                                                  |   |         |   |
| ITEM 1       |   | FINANCIAL STATEMENTS                                                                  |   | 4            |   |
|         |   |                                                                                  |   |         |   |
|  ITEM 2 |   | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |   | 18           |   |
|         |   |                                                                                  |   |         |   |
| ITEM 3       |   | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                            |   |  20     |   |
|         |   |                                                                                  |   |         |   |
| ITEM 4       |   | CONTROLS AND PROCEDURES                                                               |   | 20           |   |
|         |   |                                                                                  |   |         |   |
|         |   | PART II                                                                               |   |  21     |   |
|         |   |                                                                                  |   |         |   |
| ITEM 1       |   | LEGAL PROCEEDINGS                                                                     |   | 21           |   |
|         |   |                                                                                  |   |         |   |
| ITEM 1A      |   | RISK FACTORS                                                                          |   | 21           |   |
|         |   |                                                                                  |   |         |   |
| ITEM 2       |   | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS                           |   | 22           |   |
|         |   |                                                                                  |   |         |   |
| ITEM 3       |   | DEFAULTS UPON SENIOR SECURITIES                                                       |   | 22           |   |
|         |   |                                                                                  |   |         |   |
| ITEM 4       |   | [REMOVED AND RESERVED]                                                                |   | 22           |   |
|         |   |                                                                                  |   |         |   |
| ITEM 5       |   | OTHER INFORMATION                                                                     |   | 22           |   |
|         |   |                                                                                  |   |         |   |
| ITEM 6       |   | EXHIBITS                                                                              |   |  23     |   |
|         |   |                                                                                  |   |         |   |
|         |   | SIGNATURES                                                                            |   | 24           |   |
|         |   |                                                                                  |   |         |   |
| EXHIBIT 31.1 |   | SECTION 302 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER                          |   |         |   |
|         |   |                                                                                  |   |         |   |
| EXHIBIT 31.2 |   | SECTION 302 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER                          |   |         |   |
|         |   |                                                                                  |   |         |   |
| EXHIBIT 32.1 |   | SECTION 906 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER                          |   |         |   |
|         |   |                                                                                  |   |         |   |
| EXHIBIT 32.2 |   | SECTION 906 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER                          |   |         |   |

----

|   |    |                                                                                                                                                                                                   |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | • | risks arising from material weaknesses in our internal control over financial reporting, including material weaknesses in our control environment;                                                     |
|   |    |                                                                                                                                                                                                   |
|   | • | our ability to attract new clients and retain existing clients;                                                                                                                                        |
|   |    |                                                                                                                                                                                                   |
|   | • | our ability to retain and attract key employees;                                                                                                                                                       |
|   |    |                                                                                                                                                                                                   |
|   | • | risks associated with assumptions we make in connection with our critical accounting estimates;                                                                                                        |
|   |    |                                                                                                                                                                                                   |
|   | • | potential adverse effects if we are required to recognize impairment charges or other adverse accounting-related developments;                                                                         |
|   |    |                                                                                                                                                                                                   |
|   | • | potential downgrades in the credit ratings of our securities;                                                                                                                                          |
|   |    |                                                                                                                                                                                                   |
|   | • | risks associated with the effects of global, national and regional economic and political conditions, including fluctuations in economic growth rates, interest rates and currency exchange rates; and |
|   |    |                                                                                                                                                                                                   |
|   | • | developments from changes in the regulatory and legal environment for advertising and marketing and communications services companies around the world.                                                |

----

|   |
|--------|

| Consolidated Balance Sheets as of September 30, 2011 (Unaudited) and December 31, 2010 | Page      5 |
|----------------------------------------------------------------------------------------|-------------------------------------------|

| Consolidated Statements of Operations for the three and nine months ended September 30, 2011 and 2010 (unaudited) |   6 |
|-----------------------------------------------------------------------------------------------------------------------------|---------------|

| Consolidated Statements of Cash Flows for the nine months ended September 30, 2011 and 2010 (unaudited) |   7 |
|---------------------------------------------------------------------------------------------------------|----------|

| Statements of Stockholders Deficit for the nine months ended September 30, 2011 (Unaudited) and for the year ended December 31, 2010 |   8 |
|--------------------------------------------------------------------------------------------------------------------------------------|----------|

| Notes to Consolidated Financial Statements (Unaudited) |   9 |
|--------------------------------------------------------|----------|

----

| GENMED HOLDING CORP. AND SUBSIDIARIES                                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |
| CONSOLIDATED BALANCE SHEETS                                                                                                                                                                     |
|                                                                                                                                                                                            |   |   |   | September 30, |   |   |  December 31, |   |
|                                                                                                                                                                                            |   |   |   | 2011 |   |   | 2010 |   |
|                                                                                                                                                                                            |   |   |   | (Unaudited) |   |   |   |   |
| ASSETS                                                                                                                                                                                          |   |   |   |   |   |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |
| CURRENT ASSETS                                                                                                                                                                                  |   |   |   |   |   |   |
| Cash                                                                                                                                                                                            |   | $ | 1,267,349 |   |   | $ | 868,770 |   |
| VAT receivable                                                                                                                                                                                  |   |   | 6,647 |   |   |   | 31,890 |   |
| Amount due from related party                                                                                                                                                                   |   |   | - |   |   |   | 298,170 |   |
| Prepaid Expenses                                                                                                                                                                                |   |   | 8,095 |   |   |   | 25,916 |   |
|     Total Current Assets                                                                                                                                                    |   |   | 1,282,091 |   |   |   | 1,224,746 |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| EQUIPMENT, net of accumulated depreciation of $11,641 and $8,798 at September 30, 2011 and December 31, 2010, respectively                                                            |   |   | 5,832 |   |   |   | 8,231 |   |
| Total Assets                                                                                                                                                                                    |   | $ | 1,287,923 |   |   | $ | 1,232,977 |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                                                                                                                                           |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Accounts payable                                                                                                                                                                                |   | $ | 110,819 |   |   | $ | 175,109 |   |
| Accrued salaries                                                                                                                                                                                |   |   | 36,633 |   |   |   | 87,351 |   |
| Accrued expenses                                                                                                                                                                                |   |   | 3,399 |   |   |   | 9,511 |   |
| Accrued expenses - related parties                                                                                                                                                              |   |   | 177,975 |   |   |   | 159,037 |   |
| Loans payable to related parties                                                                                                                                                                |   |   | 42,534 |   |   |   | 119,822 |   |
|     Total Current Liabilities                                                                                                                                               |   |   | 371,360 |   |   |   | 550,830 |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| LONG TERM LIABILITIES                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| Bonds payable, net of discount of $233,440 and $0 at                                                                                                                                            |   |   |   |   |   |   |   |   |
|     September 30, 2011 and December 31, 2010, respectively                                                                                                                  |   |   | 2,350,459 |   |   |   | 1,147,534 |   |
| Subordinated convertible debentures, net of discount of                                                                                                                                         |   |   |   |   |   |   |   |   |
|     $809,160 and $1,066,198 at September 30, 2011 and                                                                                                                       |   |   |   |   |   |   |   |   |
|     December 31, 2010, respectively                                                                                                                                         |   |   | 218,499 |   |   |   | 35,114 |   |
| Total Long Term Liabilities                                                                                                                                                                     |   |   | 2,568,958 |   |   |   | 1,182,648 |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Total Liabilities                                                                                                                                                                               |   |   | 2,940,318 |   |   |   | 1,733,478 |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                                                                                                                                                   |   |   | - |   |   |   | - |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| STOCKHOLDERS' DEFICIT                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| Class A Convertible Preferred Stock, par value $0.001; authorized 500,000,000shares; there were no shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively |   |   | - |   |   |   | - |   |
| Common stock, par value $0.001; authorized 500,000,000 shares; issued and outstanding 173,813,461 and 164,977,533 shares at September 30, 2011 and December 31, 2010, respectively         |   |   | 173,812 |   |   |   | 164,976 |   |
| Additional paid-in capital                                                                                                                                                                      |   |   | 70,528,733 |   |   |   | 69,302,178 |   |
| Accumulated deficit                                                                                                                                                                             |   |   | (72,367,724 | ) |   |   | (69,995,753 | ) |
| Accumulated other comprehensive income (loss)                                                                                                                                                   |   |   | 12,784 |   |   |   | 28,098 |   |
| Total Stockholders' Deficit                                                                                                                                                                     |   |   | (1,652,395 | ) |   |   | (500,501 | ) |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Total Liabilities and Stockholders'  Deficit                                                                                                                                          |   | $ | 1,287,923 |   |   | $ | 1,232,977 |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| See accompanying notes to consolidated financial statements.                                                                                                                                    |   |
|                                                                                                                                                                                            |   |

----

| GENMED HOLDING CORP. AND SUBSIDIARIES                        |
|--------------------------------------------------------------|
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|  CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)      |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                         |   |   |   | For the Three Months Ended |   |   | For the Nine Months Ended |   |
|                                                         |   |   |   | September 30, |   |   | September 30, |   |
|                                                         |   |   |   | 2011 |   |   | 2010 |   |   | 2011 |   |   | 2010 |   |
|                                                         |   |   |   |   |   |   | Restated |   |   |   |   |   | Restated |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET SALES                                                    |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| COSTS AND EXPENSES                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Selling, general and administrative                          |   |   | 270,494 |   |   |   | 265,308 |   |   |   | 1,850,021 |   |   |   | 735,327 |   |
| Depreciation and amortization                                |   |   | 917 |   |   |   | 181,719 |   |   |   | 2,705 |   |   |   | 545,179 |   |
| Research & development                                   |   |   | 15,627 |   |   |   | 15,055 |   |   |   | 63,317 |   |   |   | 58,266 |   |
| Total Costs and Expenses                                     |   |   | 287,038 |   |   |   | 462,082 |   |   |   | 1,916,043 |   |   |   | 1,338,772 |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET OPERATING LOSS                                           |   |   | (287,038 | ) |   |   | (462,082 | ) |   |   | (1,916,043 | ) |   |   | (1,338,772 | ) |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSE)                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) on foreign exchange                            |   |   | (19,418 | ) |   |   | 55,054 |   |   |   | 43,106 |   |   |   | 12,760 |   |
| Interest expense                                             |   |   | (75,778 | ) |   |   | (16,426 | ) |   |   | (197,458 | ) |   |   | (20,237 | ) |
| Amortization - debt discount                                 |   |   | (80,846 | ) |   |   | (20,017 | ) |   |   | (301,576 | ) |   |   | (362,046 | ) |
| Total Other Income (Expense)                                 |   |   | (176,042 | ) |   |   | 18,611 |   |   |   | (455,928 | ) |   |   | (369,523 | ) |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| LOSS BEFORE INCOME TAXES                                     |   |   | (463,080 | ) |   |   | (443,471 | ) |   |   | (2,371,971 | ) |   |   | (1,708,295 | ) |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| PROVISION FOR INCOME TAXES                                   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                                     |   | $ | (463,080 | ) |   | $ | (443,471 | ) |   | $ | (2,371,971 | ) |   | $ | (1,708,295 | ) |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS PER COMMON SHARE                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (BASIC AND DILUTED)                                          |   | $ | - |   |   | $ | - |   |   | $ | (0.01 | ) |   | $ | (0.01 | ) |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| WEIGHTED AVERAGE COMMON                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| SHARES OUTSTANDING                                           |   |   | 173,813,461 |   |   |   | 161,821,489 |   |   |   | 169,108,859 |   |   |   | 149,302,895 |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See accompanying notes to consolidated financial statements. |   |
|                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

| GENMED HOLDING CORP. AND SUBSIDIARIES                                                     |
|-------------------------------------------------------------------------------------------|
|                                                                                      |   |   |   |   |   |   |
| CONSOLIDATED STATEMENTS OF CASH FLOWS                                                     |
|                                                                                      |   |   |   |   |   |   |
|                                                                                      |   |   |   |   |   |   |
|                                                                                      |   | For the nine months ended |   |
|                                                                                      |   | September 30, |   |
|                                                                                      |   | 2011 |   |   | 2010 |   |
|                                                                                      |   |   |   |   | Restated |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                      |   |   |   |   |   |   |
| Net loss                                                                                  |   | $ | (2,371,971 | ) |   | $ | (1,708,295 | ) |
| Adjustments to reconcile net loss to cash flows used in operating activities:             |   |   |   |   |   |   |   |   |
| Depreciation and amortization                                                             |   |   | 2,705 |   |   |   | 545,179 |   |
| Amortization of beneficial conversion feature                                             |   |   | 301,576 |   |   |   | 362,046 |   |
| Stock-based compensation                                                                  |   |   | 870,040 |   |   |   | - |   |
| Changes in operating assets and liabilities:                                              |   |   |   |   |   |   |   |   |
| Accounts receivable                                                                       |   |   | - |   |   |   | 60,730 |   |
| VAT receivable                                                                            |   |   | 26,982 |   |   |   | (3,735 | )  |
| Amount due from related party                                                             |   |   | 316,598 |   |   |   | - |   |
| Prepaid expenses                                                                          |   |   | 19,140 |   |   |   | - |   |
| Accounts payable                                                                          |   |   | (69,162 | ) |   |   | (88,105 | )  |
| Accrued salaries                                                                          |   |   | (50,574 | ) |   |   | (159,130 | ) |
| Accrued expenses                                                                          |   |   | 31,802 |   |   |   | - |   |
| Accrued expenses - related parties                                                        |   |   | 18,646 |   |   |   | 560,929 |   |
|     Net Cash Used in Operating Activities                             |   |   | (904,218 | ) |   |   | (430,381 | ) |
|                                                                                      |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                      |   |   |   |   |   |   |   |   |
|     Net Cash Used in Investing Activities                             |   |   | - |   |   |   | - |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                      |   |   |   |   |   |   |   |   |
| Bank overdraft                                                                            |   |   | - |   |   |   | (493 | ) |
| Proceeds from bonds payable                                                               |   |   | 1,438,056 |   |   |   | 512,198 |   |
| Advances from notes payable to related parties                                            |   |   | - |   |   |   | 17,412 |   |
| Payments on loans payable to related parties                                              |   |   | (80,383 | ) |   |   | - |   |
| Proceeds from issuance of common stock                                                    |   |   | - |   |   |   | 603,010 |   |
|         Net Cash Provided by Investing Activities |   |   | 1,357,673 |   |   |   | 1,132,127 |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| EFFECT OF CHANGE IN EXCHANGE RATE                                                         |   |   | (54,876 | ) |   |   | 31,790 |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| INCREASE IN CASH                                                                     |   |   | 398,579 |   |   |   | 733,536 |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| CASH, BEGINNING OF PERIOD                                                                 |   |   | 868,770 |   |   |   | - |   |
| CASH, END OF PERIOD                                                                       |   | $ | 1,267,349 |   |   | $ | 733,536 |   |
|                                                                                      |   |   |   |   |   |   |   |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION                                          |   |   |   |   |   |   |   |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| CASH PAID FOR:                                                                            |   |   |   |   |   |   |   |   |
| Interest                                                                                  |   | $ | 170,799 |   |   | $ | - |   |
| Taxes                                                                                     |   | $ | - |   |   | $ | - |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| NON-CASH INVESTING AND FINANCING TRANSACTIONS:                                            |   |   |   |   |   |   |   |   |
| Conversion of convertible debentures into common stock                                    |   | $ | - |   |   | $ | 1,197,952 |   |
| Conversion of accrued expenses and loans to subordinated notes                            |   | $ | - |   |   | $ | 961,912 |   |
| Conversion of subordinated convertible debentures into common stock                       |   | $ | 70,757 |   |   | $ | - |   |
| Conversion of accrued interest payable into common stock                                  |   | $ | 38,000 |   |   | $ | - |   |
| Issuance of common stock for promotional services                                         |   | $ | 20,040 |   |   | $ | - |   |
| Issuance of common stock for consultancy services                                         |   | $ | 850,000 |   |   | $ | - |   |
| Beneficial conversion feature on bonds payable charged to additional paid-in capital      |   | $ | 256,594 |   |   | $ | - |   |
|                                                                                      |   |   |   |   |   |   |   |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| See accompanying notes to consolidated financial statements.                              |
|                                                                                      |

----

| GENMED HOLDING CORP. AND SUBSIDIARIES                                                         |   |
|-----------------------------------------------------------------------------------------------|--------|
| CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT                                              |   |
| FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2011 (UNAUDITED) AND THE YEAR ENDED DECEMBER 31, 2010 |   |
|                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | Accumulated |   |   |   |   |
|                                                                                          |   | Class A Convertible |   |   |   |   |   |   |   |   | Additional |   |   |   |   |   | Other |   |   | Total |   |
|                                                                                          |   | Preferred Stock |   |   | Common Stock |   |   | Paid-In |   |   | Accumulated |   |   | Comprehensive |   |   | Stockholders |   |
|                                                                                          |   | Shares |   |   | Amount |   |   | Shares |   |   | Amount |   |   | Capital |   |   | Deficit |   |   | Income (Loss) |   |   | Deficit |   |
| Balance, December 31, 2009                                                                    |   |   | - |   |   | $ | - |   |   |   | 123,211,739 |   |   | $ | 123,212 |   |   | $ | 66,240,744 |   |   | $ | (62,266,626 | ) |   | $ | 5,765 |   |   | $ | 4,103,095 |   |
|                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Conversion of convertible debentures into common stock                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     at $0.04 per share                                                    |   |   |   |   |   |   |   |   |   |   | 29,948,794 |   |   |   | 29,948 |   |   |   | 1,168,004 |   |   |   |   |   |   |   |   |   |   |   | 1,197,952 |   |
| Issuance of Common Stock for cash at $0.05 per share                                          |   |   |   |   |   |   |   | 417,000 |   |   |   | 416 |   |   |   | 20,434 |   |   |   |   |   |   |   |   |   |   |   | 20,850 |   |
| Issuance of Common Stock for cash at $0.06 per share                                          |   |   |   |   |   |   |   | 9,200,000 |   |   |   | 9,200 |   |   |   | 572,960 |   |   |   |   |   |   |   |   |   |   |   | 582,160 |   |
| Issuance of Common Stock for cash at $0.07 per share                                          |   |   |   |   |   |   |   | 2,200,000 |   |   |   | 2,200 |   |   |   | 150,959 |   |   |   |   |   |   |   |   |   |   |   | 153,159 |   |
| Beneficial conversion features on convertible debentures                                      |   |   |   |   |   |   |   |   |   |   |   | 1,149,077 |   |   |   |   |   |   |   |   |   |   |   | 1,149,077 |   |
| Components of comprehensive loss:                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Foreign currency translation                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | 22,333 |   |   |   | 22,333 |   |
|     Net loss for the year ended December 31, 2010                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (7,729,127 | ) |   |   |   |   |   |   | (7,729,127 | ) |
|         Total comprehensive loss                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (7,706,794 | ) |
| Balance, December 31, 2010                                                                    |   |   | - |   |   |   | - |   |   |   | 164,977,533 |   |   |   | 164,976 |   |   |   | 69,302,178 |   |   |   | (69,995,753 | ) |   |   | 28,098 |   |   |   | (500,501 | ) |
|                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock for promotional services at $0.12 per share                          |   |   | 167,000 |   |   |   | 167 |   |   |   | 19,873 |   |   |   |   |   |   |   |   |   |   |   | 20,040 |   |
| Issuance of Common Stock for consultancy services at $0.17 per share                          |   |   |   |   |   |   |   | 5,000,000 |   |   |   | 5,000 |   |   |   | 845,000 |   |   |   |   |   |   |   |   |   |   |   | 850,000 |   |
| Issuance of Common Stock for conversion of accrued interest payable                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     due on subordinated convertible debentures at $0.02 per share              |   |   |   |   |   |   |   | 1,900,000 |   |   |   | 1,900 |   |   |   | 36,100 |   |   |   |   |   |   |   |   |   |   |   | 38,000 |   |
| Issuance of Common Stock for conversion of subordinated convertible                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     debenture at $0.04 per share                                               |   |   |   |   |   |   |   | 1,768,928 |   |   |   | 1,769 |   |   |   | 68,988 |   |   |   |   |   |   |   |   |   |   |   | 70,757 |   |
| Beneficial conversion features on bonds payable                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | 256,594 |   |   |   |   |   |   |   |   |   |   |   | 256,594 |   |
| Components of comprehensive loss:                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Foreign currency translation                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (15,314 | ) |   |   | (15,314 | ) |
|     Net loss for the nine months ended September 30, 2011                 |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (2,371,971 | ) |   |   |   |   |   |   | (2,371,971 | ) |
|         Total comprehensive loss                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (2,387,285 | ) |
| Balance, September 30, 2011 (Unaudited)                                                       |   |   | - |   |   | $ | - |   |   |   | 173,813,461 |   |   | $ | 173,812 |   |   | $ | 70,528,733 |   |   | $ | (72,367,724 | ) |   | $ | 12,784 |   |   | $ | (1,652,395 | ) |
|                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See accompanying notes to consolidated financial statements.                                  |
|                                                                                          |

----

----

| NOTE 1 - RESTATEMENT OF PRIOR PERIOD CONSOLIDATED FINANCIAL STATEMENTS (Continued) |   |               |        |   |
|------------------------------------------------------------------------------------|--------|--------------------|-------------|--------|
|                                                                               |   |               |        |   |   |   |   |   |   |
| CONSOLIDATED BALANCE SHEET (UNAUDITED)                                             |   |               |        |   |   |   |   |   |   |
|                                                                               |   |               |        |   |   |   |   |   |   |
|                                                                               |   | September 30, 2010 |        |
|                                                                               |   | As previously      |        |   |   |   |   | As |   |
|                                                                               |   | Reported           |        |   | Adjustments |   |   | Restated |   |
|                                                                               |   |               |        |   |   |   |   |   |   |
| ASSETS                                                                             |   |               |        |   |   |   |   |   |   |
|                                                                               |   |               |        |   |   |   |   |   |   |
| CURRENT ASSETS                                                                     |   |               |        |   |   |   |   |   |   |
| Cash                                                                               |   | $                  | 733,536     |   |   | $ | - |   |   | $ | 733,536 |   |
| Accounts receivable                                                                |   |               | 21,134      |   |   |   | - |   |   |   | 21,134 |   |
| VAT receivable                                                                     |   |               | 10,189      |   |   |   | - |   |   |   | 10,189 |   |
|     Total Current Assets                                       |   |               | 764,859     |   |   |   | - |   |   |   | 764,859 |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| EQUIPMENT, net of accumulated depreciation                                         |   |               | 9,336       |   |   |   | - |   |   |   | 9,336 |   |
| MEDICAL REGISTRATION RIGHTS, net of accumulated amortization                       |   |               | 5,607,407   |   |   |   | - |   |   |   | 5,607,407 |   |
| Total Assets                                                                       |   | $                  | 6,381,602   |   |   | $ | - |   |   | $ | 6,381,602 |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                               |   |               |        |   |   |   |   |   |   |   |   |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                                |   |               |        |   |   |   |   |   |   |   |   |   |
| Accounts payable                                                                   |   | $                  | 178,575     |   |   | $ | - |   |   | $ | 178,575 |   |
| Accrued salaries                                                                   |   |               | 147,014     |   |   |   | - |   |   |   | 147,014 |   |
| Accrued expenses                                                                   |   |               | 164,102     |   |   |   | (164,102 | ) |   |   | - |   |
| Accrued expenses - related parties                                                 |   |               | -           |   |   |   | 172,102 |   |   |   | 172,102 |   |
| Subordinated notes                                                                 |   |               | 969,912     |   |   |   | (969,912 | ) |   |   | - |   |
| Notes payable                                                                      |   |               | 512,198     |   |   |   | (512,198 | ) |   |   | - |   |
| Loans payable to related parties                                                   |   |               | 172,736     |   |   |   | - |   |   |   | 172,736 |   |
|     Total Current Liabilities                                  |   |               | 2,144,537   |   |   |   | (1,474,110 | ) |   |   | 670,427 |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| LONG TERM LIABILITIES                                                              |   |               |        |   |   |   |   |   |   |   |   |   |
| Bonds payable                                                                      |   |               | -           |   |   |   | 512,198 |   |   |   | 512,198 |   |
| Subordinated convertible debentures, net of discount                               |   |               | -           |   |   |   | 20,017 |   |   |   | 20,017 |   |
| Total Long Term Liabilities                                                        |   |               | -           |   |   |   | 532,215 |   |   |   | 532,215 |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| Total Liabilities                                                                  |   |               | 2,144,537   |   |   |   | (941,895 | ) |   |   | 1,202,642 |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                                      |   |               | -           |   |   |   | - |   |   |   | - |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| STOCKHOLDERS' EQUITY                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| Class A Convertible Preferred Stock                                                |   |               | -           |   |   |   | - |   |   |   | - |   |
| Common stock                                                                       |   |               | 162,776     |   |   |   | - |   |   |   | 162,776 |   |
| Additional paid-in capital                                                         |   |               | 68,964,054  |   |   |   | - |   |   |   | 68,964,054 |   |
| Accumulated deficit                                                                |   |               | (64,916,816 | )      |   |   | 941,895 |   |   |   | (63,974,921 | ) |
| Accumulated other comprehensive income (loss)                                      |   |               | 27,051      |   |   |   | - |   |   |   | 27,051 |   |
| Total Stockholders' Equity                                                         |   |               | 4,237,065   |   |   |   | 941,895 |   |   |   | 5,178,960 |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |
| Total Liabilities and Stockholders'  Equity                              |   | $                  | 6,381,602   |   |   | $ | - |   |   | $ | 6,381,602 |   |
|                                                                               |   |               |        |   |   |   |   |   |   |   |   |   |

----

| NOTE 1 - RESTATEMENT OF PRIOR PERIOD CONSOLIDATED FINANCIAL STATEMENTS (Continued) |   |
|------------------------------------------------------------------------------------|--------|
|                                                                               |   |   |   |   |   |   |   |   |   |
| CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)                                  |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |
|                                                                               |   | For the Nine Months Ended September 30, 2010 |   |
|                                                                               |   | As previously |   |   |   |   |   | As |   |
|                                                                               |   | reported |   |   | Adjustments |   |   | Restated |   |
|                                                                               |   |   |   |   |   |   |   |   |   |
| NET SALES                                                                          |   | $ | 4,648 |   |   | $ | (4,648 | ) |   | $ | - |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| COSTS AND EXPENSES                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| Selling, general and administrative                                                |   |   | 739,975 |   |   |   | (4,648 | ) |   |   | 735,327 |   |
| Depreciation and amortization                                                      |   |   | 545,179 |   |   |   | - |   |   |   | 545,179 |   |
| Research & development                                                         |   |   | 58,266 |   |   |   | - |   |   |   | 58,266 |   |
| Total Costs and Expenses                                                           |   |   | 1,343,420 |   |   |   | (4,648 | ) |   |   | 1,338,772 |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| NET OPERATING LOSS                                                                 |   |   | (1,338,772 | ) |   |   | - |   |   |   | (1,338,772 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSE)                                                             |   |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) on foreign exchange                                                  |   |   | 12,760 |   |   |   | - |   |   |   | 12,760 |   |
| Interest expense                                                                   |   |   | (1,324,178 | ) |   |   | 1,303,941 |   |   |   | (20,237 | ) |
| Amortization - debt discount                                                       |   |   | - |   |   |   | (362,046 | ) |   |   | (362,046 | ) |
| Total Other Income (Expense)                                                       |   |   | (1,311,418 | ) |   |   | 941,895 |   |   |   | (369,523 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| LOSS BEFORE INCOME TAXES                                                           |   |   | (2,650,190 | ) |   |   | 941,895 |   |   |   | (1,708,295 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| PROVISION FOR INCOME TAXES                                                         |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                                                           |   | $ | (2,650,190 | ) |   | $ | 941,895 |   |   | $ | (1,708,295 | ) |

----

| NOTE 1 - RESTATEMENT OF PRIOR PERIOD CONSOLIDATED FINANCIAL STATEMENTS (Continued) |   |
|------------------------------------------------------------------------------------|--------|
|                                                                               |   |   |   |   |   |   |   |   |   |
| CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)                                  |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |
|                                                                               |   | For the Three Months Ended September 30, 2010 |   |
|                                                                               |   | As previously |   |   |   |   |   | As |   |
|                                                                               |   | reported |   |   | Adjustments |   |   | Restated |   |
|                                                                               |   |   |   |   |   |   |   |   |   |
| NET SALES                                                                          |   | $ | 4,145 |   |   | $ | (4,145 | ) |   | $ | - |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| COSTS AND EXPENSES                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| Selling, general and administrative                                                |   |   | 269,453 |   |   |   | (4,145 | ) |   |   | 265,308 |   |
| Depreciation and amortization                                                      |   |   | 181,719 |   |   |   | - |   |   |   | 181,719 |   |
| Research & development                                                         |   |   | 15,055 |   |   |   | - |   |   |   | 15,055 |   |
| Total Costs and Expenses                                                           |   |   | 466,227 |   |   |   | (4,145 | ) |   |   | 462,082 |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| NET OPERATING LOSS                                                                 |   |   | (462,082 | ) |   |   | - |   |   |   | (462,082 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSE)                                                             |   |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) on foreign exchange                                                  |   |   | 55,054 |   |   |   | - |   |   |   | 55,054 |   |
| Interest expense                                                                   |   |   | (978,338 | ) |   |   | 961,912 |   |   |   | (16,426 | ) |
| Amortization - debt discount                                                       |   |   | - |   |   |   | (20,017 | ) |   |   | (20,017 | ) |
| Total Other Income (Expense)                                                       |   |   | (923,284 | ) |   |   | 941,895 |   |   |   | 18,611 |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| LOSS BEFORE INCOME TAXES                                                           |   |   | (1,385,366 | ) |   |   | 941,895 |   |   |   | (443,471 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| PROVISION FOR INCOME TAXES                                                         |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                                                           |   | $ | (1,385,366 | ) |   | $ | 941,895 |   |   | $ | (443,471 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |

----

| NOTE 1 - RESTATEMENT OF PRIOR PERIOD CONSOLIDATED FINANCIAL STATEMENTS (Continued)        |   |                                         |       |   |
|-------------------------------------------------------------------------------------------|--------|----------------------------------------------|------------|--------|
|                                                                                      |   |                                         |       |   |   |   |   |   |   |
| CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)                                         |   |                                         |       |   |   |   |   |   |   |
|                                                                                      |   |                                         |       |   |   |   |   |   |   |
|                                                                                      |   | For the Nine Months Ended September 30, 2010 |       |
|                                                                                      |   | As previously                                |       |   |   |   |   | As |   |
|                                                                                      |   | Reported                                     |       |   | Adjustments |   |   | Restated |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                      |   |                                         |       |   |   |   |   |   |   |
| Net loss                                                                                  |   | $                                            | (2,650,190 | )      |   | $ | 941,895 |   |   | $ | (1,708,295 | ) |
| Adjustments to reconcile net loss to cash flows used in operating activities:             |   |                                         |       |   |   |   |   |   |   |   |   |   |
| Depreciation and amortization                                                             |   |                                         | 545,179    |   |   |   | - |   |   |   | 545,179 |   |
| Amortization of beneficial conversion feature                                             |   |                                         | 1,303,941  |   |   |   | (941,895 | ) |   |   | 362,046 |   |
| Changes in operating assets and liabilities:                                              |   |                                         |       |   |   |   |   |   |   |   |   |   |
| Accounts receivable                                                                       |   |                                         | 60,730     |   |   |   | - |   |   |   | 60,730 |   |
| VAT receivable                                                                            |   |                                         | (3,735     | )      |   |   | - |   |   |   | (3,735 | ) |
| Accounts payable                                                                          |   |                                         | (88,105    | )      |   |   | - |   |   |   | (88,105 | ) |
| Accrued salaries                                                                          |   |                                         | (159,130   | )      |   |   | - |   |   |   | (159,130 | ) |
| Accrued expenses                                                                          |   |                                         | 560,929    |   |   |   | (560,929 | ) |   |   | - |   |
| Accrued expenses - related parties                                                        |   |                                         | -          |   |   |   | 560,929 |   |   |   | 560,929 |   |
|     Net Cash Used in Operating Activities                             |   |                                         | (430,381   | )      |   |   | - |   |   |   | (430,381 | ) |
|                                                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |
|     Net Cash Used in Investing Activities                             |   |                                         | -          |   |   |   | - |   |   |   | - |   |
|                                                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |
| Bank overdraft                                                                            |   |                                         | (493       | )      |   |   | - |   |   |   | (493 | ) |
| Proceeds from bonds payable                                                               |   |                                         | 512,198    |   |   |   | - |   |   |   | 512,198 |   |
| Advances from notes payable to related parties                                            |   |                                         | 17,412     |   |   |   | - |   |   |   | 17,412 |   |
| Proceeds from issuance of common stock                                                    |   |                                         | 603,010    |   |   |   | - |   |   |   | 603,010 |   |
|         Net Cash Provided by Investing Activities |   |                                         | 1,132,127  |   |   |   | - |   |   |   | 1,132,127 |   |
|                                                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |
| EFFECT OF CHANGE IN EXCHANGE RATE                                                         |   |                                         | 31,790     |   |   |   | - |   |   |   | 31,790 |   |
|                                                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |
| INCREASE IN CASH                                                                          |   |                                         | 733,536    |   |   |   | - |   |   |   | 733,536 |   |
|                                                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |
| CASH, BEGINNING OF PERIOD                                                                 |   |                                         | -          |   |   |   | - |   |   |   | - |   |
| CASH, END OF PERIOD                                                                       |   | $                                            | 733,536    |   |   | $ | - |   |   | $ | 733,536 |   |
|                                                                                      |   |                                         |       |   |   |   |   |   |   |   |   |   |

----

----

----

|  Year Ending       |   | Notes  |      |   | Loans  |   |
|-------------------------|--------|--------|-----------|--------|--------|--------|
|  December 31, 2011 |   | $      | -         |   |   | $      | 119,822 |   |
|  December 31, 2012 |   |   | -         |   |   |   | - |   |
|  December 31, 2013 |   |   | -         |   |   |   | - |   |
|  December 31, 2014 |   |   | 1,101,312 |   |   |   | - |   |
|  December 31, 2015 |   |   | -         |   |   |   | - |   |
|  Thereafter        |   |   | -         |   |   |   | - |   |
|  Total             |   | $      | 1,101,312 |   |   | $      | 119,822 |   |

----

| Year Ending             |   | Amount |      |
|-------------------------|--------|--------|-----------|
|  December 31, 2011 |   | $      | -         |   |
|  December 31, 2012 |   |   | -         |   |
|  December 31, 2013 |   |   | -         |   |
|  December 31, 2014 |   |   | 1,147,534 |   |
|  December 31, 2015 |   |   | -         |   |
|  Total             |   | $      | 1,147,534 |   |

----

----

----

----

| ·   | As of September 30, 2011, there was a lack of accounting personnel with the requisite knowledge of Generally Accepted Accounting Principles (“GAAP”) in the US and the financial reporting requirements of the Securities and Exchange Commission. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | As of September 30, 2011, there were insufficient written policies and procedures to insure the correct application of accounting and financial reporting with respect to current requirements of GAAP and SEC disclosure requirements. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | As of September 30, 2011, there was a lack of segregation of duties, in that we had only one person performing all accounting-related duties. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | As of September 30, 2011, there were no independent directors and no independent audit committee. |
|--------------------|---------------------------------------------------------------------------------------------------|

----

----

| Exhibit    10.1 | Stock Exchange Agreement between the Company and Joost de Metz (“de Metz”), Willem Blijleven (“Blijleven”), Erwin R. Bouwens (“Bouwens”) and Medical Network Holding BV dated April 17, 2008, incorporated herein by reference to Exhibit 9.2 to the Form 8-K current  report of the Company filed on May 2, 2008. |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    10.2 | General Release and Settlement Agreement, incorporated herein by reference to Exhibit 9.1 to the Form 8-K current report of the Company filed on May 2, 2008. |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    10.3 | Consulting Agreement between the Company and London Finance Group, Ltd., | incorporated herein by reference to Exhibit 9.1 to the Form 8-K current report of the Company filed on May 2, 2008. |
|-------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|

| Exhibit    10.4 | Release and Settlement Agreement between the Company, Joost de Metz, Willem Blijleven,  E.R. Bouwens Beheermaatschappij B.V., Medical Network Holding BV, Total Look, BV, London Finance Group, Ltd.,  Dojo Enterprises, LLC,  Hyperion Fund, L.P.,  The Palisades Capital, LLC 401(k) Profit Sharing Trust, The Morpheus 2005 Trust dated December 1, 2005, Burton Partners, LLC, Picasso, LLC  and Glacier, LLC, incorporated herein by reference to Exhibit 10.2 to the Form 10-K annual report of the Company filed on May 15, 2009. |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    31.1 | Certification of the Principal Executive Officer Pursuant to Rule 13A-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    31.2 | Certification of the Principal Financial Officer Pursuant to Rule 13A-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    32.1 | Certification of the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    32.2 | Certification of the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Dated:  November 18, 2011 | Genmed Holding Corp.                 |
|------------------------------------------|--------------------------------------|
|                                     |                                 |
|                                     |                                 |
|                                     | By: /s/ Randy Hibma                  |
|                                     | Randy Hibma, Chief Financial Officer |

----